Mary Belford, MD
Psychiatry · Palos Heights, ILNPI 1194719534
Payments from drug & device makers
Across 398 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$824
- Lundbeck LLC$741
- Otsuka America Pharmaceutical, Inc.$712
- Indivior Inc.$577
- Johnson & Johnson$548
- Alkermes, Inc.$442
- plus $4K from 20 others
What the payments were for
- Food & beverage$7,29899%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 41 | $824 |
| Lundbeck LLC | 42 | $741 |
| Otsuka America Pharmaceutical, Inc. | 42 | $712 |
| Indivior Inc. | 23 | $577 |
| Johnson & Johnson | 32 | $548 |
| Alkermes, Inc. | 21 | $442 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $439 |
| Teva Pharmaceuticals USA, Inc. | 22 | $336 |
| Supernus Pharmaceuticals, Inc. | 16 | $330 |
| Ironshore Pharmaceuticals Inc. | 15 | $321 |
| Neurocrine Biosciences, Inc. | 15 | $320 |
| Sunovion Pharmaceuticals Inc. | 21 | $257 |
| Corium, LLC | 12 | $245 |
| Axsome Therapeutics, Inc. | 11 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $229 |
| Almatica Pharma LLC | 12 | $193 |
| Idorsia Pharmaceuticals US Inc | 8 | $115 |
| Tris Pharma Inc | 5 | $89 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| Acadia Pharmaceuticals Inc | 5 | $71 |
| Merck | 3 | $56 |
| Neos Therapeutics, LP | 3 | $50 |
| Eisai Inc. | 3 | $45 |
| Shire North American Group Inc | 3 | $42 |
| Biogen | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$7,345 in reported general payments places this provider in the 90th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 41 | $100,511 |
| Abilify MaintenaAripiprazole | 32 | $96,451 |
| RexultiBrexpiprazole | 28 | $57,983 |
| Risperidone ErRisperidone Microspheres | 26 | $42,841 |
| Lurasidone Hcl | 108 | $42,467 |
| FanaptIloperidone | 30 | $26,661 |
| VraylarCariprazine Hcl | 15 | $22,251 |
| Aripiprazole | 264 | $22,009 |
| CaplytaLumateperone Tosylate | 11 | $18,377 |
| Clozapine OdtClozapine | 20 | $13,368 |
| Divalproex Sodium | 253 | $12,299 |
| TrintellixVortioxetine Hydrobromide | 19 | $11,987 |
| Quetiapine Fumarate | 409 | $11,029 |
| Ziprasidone Hcl | 102 | $8,505 |
| Clozapine | 127 | $8,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $712 | $154,43460 claims |
| Johnson & JohnsonInvega Sustenna | $548 | $100,51141 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $72 | $26,66130 claims |
| AbbVieVraylar | $824 | $22,25115 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $439 | $18,37711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $229 | $11,98719 claims |
| Almatica Pharma LLCSertraline Hcl | $193 | $2,602266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Palos Heights
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.